Is Ketamine Addictive? K-Cramps and Bladder Damage

Yes. Not the way opioids are, but the psychological pull is real, well documented, and badly underrated in harm reduction conversations. The bigger problem for most heavy users is not the dependence itself but what it drags along with it: ketamine-induced uropathy, damage to the bladder and urinary tract that reverses if you stop early and does not reverse if you don’t.

What dependence looks like here

Ketamine is an NMDA receptor antagonist, blocking glutamate transmission, with effects that scale from mild dissociation up to the near-total anaesthesia of a k-hole. It is Schedule III in the US.

The dependence is mostly psychological, and that word does a lot of unfair work. Case series and surveys describe the same arc repeatedly: dose and frequency climb, cravings get strong, more of the week goes to obtaining and using, and use continues past the point of obvious physical harm. Morgan and Curran’s 2010 work in Addiction found that people using more than four days a week showed significant memory impairment, dissociative symptoms and strong urges to use, which is the standard picture of a substance use disorder.

Physical withdrawal exists and is milder than opioids or alcohol. No seizures, nothing life-threatening. Heavy daily users who stop abruptly report anxiety, dysphoria, insomnia, tremor and sweating over the following 24 to 72 hours. Those symptoms are real and they drive relapse, so calling them “just psychological” gets the experience wrong.

Tolerance builds fast, through NMDA receptor downregulation, and that matters more than it sounds. Chasing the same dissociation means escalating the dose, and cumulative dose is what appears to drive the bladder damage. The tolerance and the uropathy are the same story.

K-cramps are not a stomach problem

“K-cramps” is the community name for episodes of severe, colicky pain in the upper abdomen that can leave people unable to stand up straight. It gets treated as a nuisance side effect. It isn’t one.

The pain often reflects the upper urinary tract, the ureters and kidneys, rather than the bladder alone. Chu and colleagues, writing in BJU International in 2008, were among the first to describe the syndrome systematically: patients with severe lower urinary tract symptoms who also had hydronephrosis, fluid backing up into the kidneys from obstructed ureters. That obstruction is where the flank and upper abdominal pain comes from.

So K-cramps mean the damage has already moved past the bladder. Continuing to use from that point risks progressive loss of kidney function from chronic obstruction, ureteral strictures that need surgery, and irreversible renal damage.

If you are getting K-cramps, stop and see a urologist. This is not a symptom to medicate around.

How the bladder gets destroyed

Ketamine and its main metabolite norketamine appear to be directly toxic to the urothelium, the lining of the bladder and urinary tract. The full mechanism is still being worked out, but the pieces are consistent: drug and metabolite excreted in urine sit against the bladder wall and irritate it chemically, an inflammatory response follows, and submucosal fibrosis, scarring under the lining, sets in.

The bladder that results is stiff. It cannot stretch, so it cannot hold normal volumes, it contracts often and urgently, and filling hurts. In severe disease the fibrosis pushes through the wall into surrounding structures.

What that feels like, in the order people usually notice it:

• Frequency. Needing to go constantly, sometimes several times an hour.
• Urgency. A sudden urge you cannot put off.
• Dysuria. Pain or burning when you urinate.
• Hematuria. Blood in the urine, in some cases.
• Shrinking capacity. In a surgical series of 14 refractory cases, mean cystometric capacity was 50.9 mL against a normal 400 to 600 mL. That is the severe end of the spectrum, not the typical user.
• Upper tract involvement. Flank pain, hydronephrosis, kidney impairment in advanced disease.

Early is reversible, late is not

This is the sentence the rest of the post exists for. Middela and Pearce’s 2011 systematic review in the Annals of the Royal College of Surgeons of England found that patients who stopped early in the disease course improved significantly. Patients who kept using despite symptoms progressed to fibrotic damage that does not come back.

At the far end of the published case series, people have needed cystectomy: surgical removal of the bladder. That outcome is entirely preventable by stopping when the first symptoms appear, which is also the point at which stopping feels least urgent.

What “heavy use” means in the case reports

The pattern in the literature is specific: daily or near-daily use, sustained over months to years, frequently at gram-per-day doses. Wood and colleagues reported a UK emergency department series in BJU International in 2011 in which every patient had been using heavily and frequently. None were occasional recreational users. The shortest exposure before symptoms in that series was around a year of regular heavy use.

Do not read that as a safe window. Individual variation exists, and the honest limitation is bigger than that: these are case series, near the bottom of the evidence hierarchy. They capture people who developed the condition, not everyone who used heavily, so there is no population incidence figure to give you. What is solid is the direction: heavy daily use is the consistent risk factor, and the condition is real.

Memory, in frequent users

Separately from the bladder, chronic heavy use tracks with cognitive impairment. Morgan and colleagues followed users prospectively over a year, also in Addiction, and found frequent users showed progressively worsening episodic memory and rising dissociative symptoms across the study period, while occasional users and non-users did not. The effect was dose- and frequency-dependent, which fits what NMDA antagonism does to hippocampal function.

Again, frequent users. The evidence does not show meaningful cognitive harm from infrequent recreational use at low doses.

Where the line actually is

Recreational use looks like infrequent occasions, a dose that stays flat or drops over time, no distress about skipping a planned night, and no physical symptoms.

Dependence looks like:

• Frequency climbing from occasional to several times a week to daily
• Needing more for the same effect
• Using to feel normal, or to manage the anxiety of not having any, rather than for the experience
• Continuing through physical symptoms, damaged relationships, money or work problems
• Deciding to stop and finding you can’t
• Thinking about the next time, arranging your week around access

And three things that mean get seen now, not next month: any urinary symptom at all, K-cramps, or blood in the urine.

If symptoms show up

1. Stop. Continuing after uropathy symptoms is the specific thing that turns reversible damage into permanent fibrosis.
2. See a urologist, not only a GP. This needs urodynamic testing, imaging to check for hydronephrosis, and urine analysis. General practice may not recognise it.
3. Tell them what you’ve been taking. Urologists who see this condition recognise it, but they need the history. They are not there to judge you.
4. Give it time. Where abstinence leads to recovery, improvement takes weeks to months. Symptoms that persist after sustained abstinence mean the damage is fixed.
5. Ask for help with the stopping. If you have tried and couldn’t, that is clinical information, not a character flaw.

One interaction worth flagging, since it kills people faster than the bladder does: ketamine with alcohol or any other CNS depressant sharply raises the risk of respiratory depression and loss of protective airway reflexes. Check the interaction checker before combining anything.

Spravato is a different exposure

Esketamine for treatment-resistant depression is given nasally at 56 to 84 mg per session under clinical supervision, two or three times weekly during induction and less often after that. In dose and pattern that is a different drug exposure from gram-a-day recreational use, and clinical trials have not flagged uropathy as a significant adverse event at those doses.

Not zero, though. A 2024 case report documented ketamine-induced cystitis in a patient on therapeutic ketamine. If you are prescribed it and worried, raise it with your prescriber rather than stopping on your own.

The dependence here is manageable and the bladder damage is preventable, but only in one direction: symptoms first, then stopping. K-cramps and urinary changes are not side effects to push through. They are the window closing.

For dosing, effects and the rest, see the ketamine guide, and the detail on bladder damage if that is the part you came for.

Sources

PMID 38166893 | PMID 19133891 | PMID 23996856 | PMID 21314885 | PMID 19919593